Advances in STI Testing: Exploring the potential of mPOC solutions

Dr. Rebecca Lillis
STI Testing: Getting to the Point of Care

In 2020, there were 211 million new cases of chlamydia and gonorrhea worldwide among adults aged 15 to 491. If not treated properly, these infections can cause serious health issues like infertility and ectopic pregnancy. This is particularly problematic in regions with limited access to lab resources, where heavy reliance on symptoms often results in frequent misdiagnosis and inadequate treatment.

Dr. Rebecca Lillis, a renowned expert in infectious diseases, shares her insight on the benefits of Molecular Point-of-Care (mPOC) testing for STIs (sexually transmitted infections). This technology brings precise lab-quality diagnostics directly to the point of care, significantly improving the speed and accuracy of STI diagnoses.This ensures appropriate treatment for symptomatic patients, thereby reducing unnecessary treatments, hospital visits, and overall healthcare costs. Dr. Lillis also addresses challenges in traditional clinical workflows without mPOC testing and presents research showing that rapid mPOC testing improves treatment outcomes and optimizes antibiotic use.

Furthermore, Dr. Lillis highlights how mPOC testing enhances satisfaction for both patients and providers. Current mPOC STI tests can deliver results within 30 to 90 minutes2 , allowing diagnosis and treatment to happen in just one visit. This reduces patient waiting time and the need for follow-up communication, which is particularly beneficial where follow-up is difficult. 

Please enjoy this informative webinar!



  1. Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. (2021, May 20). World Health Organization (WHO). Retrieved June 13, 2024, from
  2. FDA Allows for First Point-of-Care Chlamydia and Gonorrhea Test to be Used in More Near-Patient Care Settings. (2021, March 30). FDA. Retrieved June 13, 2024, from

The views and opinions expressed in this webinar are those of the speakers and do not necessarily reflect the views or positions of Roche or any other sponsors.


Dr. Rebecca Lillis is an accomplished expert in Infectious Diseases with a strong academic background and extensive practical experience, blending academic excellence with extensive practical experience. She currently holds the position of Associate Professor of Clinical Medicine at Louisiana State University School of Medicine in New Orleans. Before  transitioning into a teaching role, Dr. Lillis earned her M.D. from LSU, where she completed her residency and chief residency in Internal Medicine, as well as pursued further training in Infectious Diseases.

Dr. Lillis’s expertise spans research, clinical practice, and teaching. Her research focuses primarily on sexually transmitted infections (STIs), specifically Mycoplasma genitalium infections and bacterial vaginosis transmission. Dr. Lillis actively participates in clinical trials and pharmaceutical research at the LSU-CrescentCare Sexual Health Center, where she also dedicates her time to patient care and teaching infectious disease consultation services.


Register now


Join us in the world of POCT.

Learn from healthcare professionals around the world as they share their expertise and experiences in Point of Care Testing. Gain valuable insights, be inspired, and expand your knowledge.
Sign up now for upcoming ASPIRE Point of Care webinars!

Form Successfully Submitted!
Thank you for your submission!